Dolutegravir-Emtricitabine-Tenofovir Alafenamide Tablets 50mg-300mg-300mg Tablets_Laurus_6493

Medicines Control Authority of Zimbabwe Follow

Medicines Control Authority of Zimbabwe @mcazofficial ·

2 Oct

1/ 📣INVITATION: The Authority invites Medicines and Medical products registration applicants and other relevant stakeholders to participate in a virtual meeting titled "Unpacking the New Medicines Registration Processes in Zimbabwe and Mapping Future Expectations"

Reply on Twitter 1841411036965953959 Retweet on Twitter 1841411036965953959 7 Like on Twitter 1841411036965953959 14 Twitter 1841411036965953959

Medicines Control Authority of Zimbabwe @mcazofficial ·

25 Sep

MCAZ commemorates #WorldPharmacistsDay

Happy World Pharmacists day 💊to the pharmacist community

#WorldPharmacistsDay
#WorldPharmacistsDay2024
#Pharmacist

Reply on Twitter 1838893359731036209 Retweet on Twitter 1838893359731036209 3 Like on Twitter 1838893359731036209 21 Twitter 1838893359731036209

NatPharm Zimbabwe @natpharmz ·

21 Sep

The NatPharm Board is pleased to announce the appointment of Newman Batanayi Madzikwa as new Managing Director, effective 01/09/24. Madzikwa is a distinguished pharmacist with extensive experience, including @MoHCCZim , the UN & private. @LivUni
@livuniglobal @UniversityOfZim

Reply on Twitter 1837449540674207801 Retweet on Twitter 1837449540674207801 4 Like on Twitter 1837449540674207801 31 Twitter 1837449540674207801

Medicines Control Authority of Zimbabwe @mcazofficial ·

17 Sep

Condolence Message
It is with deep sorrow that we learnt of the passing of Air Commodore (Rtd) PGS Zimondi. The late Zimondi was a valued Board member of the Authority.

Our thoughts and prayers are with the Zimondi family, and all who were touched by his exceptional service.

Reply on Twitter 1836026154941047078 Retweet on Twitter 1836026154941047078 2 Like on Twitter 1836026154941047078 9 Twitter 1836026154941047078

Dolutegravir-Emtricitabine-Tenofovir Alafenamide Tablets 50mg-300mg-300mg Tablets_Laurus_6493

QUICK LINKS

FACEBOOK FEED

TWITTER FEED

CONTACT US